Company OverviewCoronary Artery DiseaseTechnical ResourcesEmployment OpportunitiesWhat's New


Boston, September 12, 2000/PRNewswire/...Percardia Inc., a privately held medical device company focused on the development of new therapeutic interventions (VCAB™ Surgical Delivery System, VSTENT™ Myocardial Implant) for the treatment of coronary artery disease, announced today the recent appointments of Michael E. Reinhardt, as Vice President of Marketing and Christopher P. Joyce, as Chief Financial Officer.

Mr. Reinhardt joins Percardia from Boston Scientific Corporation, Scimed Division where he held progressive management positions within marketing. Most recently he was Director of Marketing with global responsibility for SCIMED's intravascular ultrasound and rotational atherectomy franchises. Prior to that he has spent several years with the Boston Scientific International Division where he had marketing responsibilities for the full line of interventional cardiology products including the successful launch and establishment of SCIMED's intravascular ultrasound and Rotablator™ product lines in Japan. Mr. Reinhardt bring over 12 years of medical device marketing and sales experience, including 5 years at Ethicon, Inc and Ethicon Endosurgery where he held various sales and marketing positions. He has earned his undergraduate Degree in Marketing from Ohio University and his Masters of Business Administration from Baruch College.

Mr. Joyce joins Percardia from XTRA Corporation, a leading lessor of freight transportation equipment, where he spent 15 years including the last 7 years in the role of Vice President and Treasurer. He has experience managing all aspects of corporate finance including corporate strategy, implementation, the raising of significant levels of debt and equity capital as well as completing acquisitions and divestitures activities. Mr. Joyce brings a proven track record of building beneficial relationships with bankers, analysts and investors. He earned a Bachelor of Science degree from the University of Massachusetts and a Masters of Business Administration from Babson College.

Nancy Briefs, President and Chief Executive Officer of Percardia said, "The Board of Directors and the rest of the management team is pleased to have recruited Michael and Chris since their addition now completes the senior management team for the company." Ms. Briefs went on to note, "Mr. Reinhardt's broad marketing background in medical devices, especially in his market development experience in interventional cardiology and minimally invasive surgery are a great match for Percardia. Mr. Joyce's experience and relationships with the financial community will be a real asset for Percardia as the company progresses through the various stages of funding."

Percardia's proprietary technology is based on intellectual property licensed from Peter J. Wilk, MD a noted surgeon and investor. The VCAB™ Surgical Delivery System creates a channel from the ventricle to the coronary artery by placing a stent through the heart wall. The company is backed by several leading investors including, Atlas Ventures, Crescendo Ventures, Vanguard Venture Partners and Medtronic, Inc. For more information, please call Percardia at 603.882.1803.

Press Releases | Events

Company | Coronary Artery Disease | Resources | Employment | What's New

Percardia Inc.
Heron Cove Office Park
10 Al Paul Lane, Suite 202
Merrimack, NH 03054
© 2001 Percardia Inc.